Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics Inc
(NQ:
VTGN
)
4.660
-0.110 (-2.31%)
Streaming Delayed Price
Updated: 11:17 AM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vistagen Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports Positive PH15 Data from Pilot Study Showing Psychomotor Impairment Improvement
April 25, 2024
Via
Investor Brand Network
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
April 25, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation at Upcoming Anxiety and Depression Association Conference
April 09, 2024
Via
Investor Brand Network
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
April 09, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
April 01, 2024
Via
Investor Brand Network
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
April 01, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days
March 11, 2024
Via
Investor Brand Network
Vistagen to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference
February 28, 2024
Via
Investor Brand Network
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update
February 14, 2024
Via
Investor Brand Network
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call
February 06, 2024
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
February 06, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
December 27, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
December 27, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2024 Financial Report, Corporate Update
November 10, 2023
Via
Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
November 09, 2023
From
Vistagen
Via
Business Wire
Vistagen to Present at Stifel 2023 Healthcare Conference
November 08, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Plans to Present Positive Study Results at Conferences in November
November 07, 2023
Via
Investor Brand Network
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
November 07, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q2 Results, Corporate Update Conference Call
November 06, 2023
Via
Investor Brand Network
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
November 06, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Inaugural Biotech CNS/Neuro Summit
October 05, 2023
Via
Investor Brand Network
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Pricing of $100M Underwritten Offering
October 02, 2023
Via
Investor Brand Network
Vistagen Announces Pricing of $100 Million Underwritten Offering
October 02, 2023
From
Vistagen Therapeutics, Inc.
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports on Phase 2A Study Results Regarding Treatment of Premenstrual Dysphoric Disorder
September 12, 2023
Via
Investor Brand Network
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
September 12, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), Fuji Pharma Co. Ltd. (TSE: 4554) Announce Exclusive Negotiation Agreement
September 05, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.